We have shown that MM-121 was able to abrogate HER3 signaling-mediated resistance to trastuzumab and paclitaxel in HER2-over-expressing breast cancer cells via the inactivation of HER3 and its downstream PI-3 K/Akt signaling [89, 90]. Here, ERBB2 is linked to breast carcinoma.